Inflammatory bowel disease associated knowledge in South Indian populations: rational Study

Sathyaprabha Gopalan^{1,2,} Srinivasan Nagarajan¹, Aravindh Somasundaram³, Manisenthilkumar Kulanthaivelu Thiyagarajan⁴

- 1. Department of Pharmacy, Annamalai University, Chidambaram, (Tamil Nadu) India.
- 2. Department of Pharmacy Practice, KMCH College of Pharmacy (Affiliated to TN. Dr.M. G. R. Medical University), Coimbatore, (Tamil Nadu) India.
- 3. Department of Gastroenterology, Kovai Medical Center and Hospital, Coimbatore, (Tamil Nadu) India.
- 4. Department of Pharmacy and Quality Control, Royal Care Super Specialty Hospital, Coimbatore, (Tamil Nadu), India.

Abstract

Background:

Objectives: The pivotal of the study was to compare the effectiveness of education in disease-associated knowledge of Inflammatory Bowel Disease (IBD) patients between pre-test and post-test using the IBD-KNOW questionnaire and patient educational resources.

Methods: This study used a patient proforma and IBD- KNOW questionnaire to perform the study prospectively by interviewing method. The patient selection was based on inclusion and exclusion criteria by convenient sampling technique from November 2018 to July 2019 at a multispecialty hospital. Knowledge scores and inter-item correlation were calculated between the pre-test and post-test by R Programming software with p<0.05.

Results: Among 40 patients with IBD diagnosis, the baseline sociodemographic characteristics were recorded. The response rate of IBD knowledge between the pre-test and post-test resulted in significant differences with varying scales but the response rate was lesser in the domains of management and pregnancy-based questions in the pre-test and post-test.

Conclusions: Recently there was a swift in IBD incidence, this may be improved by affording suitable patient education and counseling for further knowledge level in managing the disease by coping strategy. On comparison between the pre-test and post-test, this study recommends innovative educational methods to enable continuing education for chronic disease which can be easily accessible and reliable for IBD patients.

Keywords: Inflammatory bowel disease; South Indian populations.

DOI: https://dx.doi.org/10.4314/ahs.v23i2.51

Cite as: Gopalan S, Nagarajan S, Somasundaram A, Thiyagarajan MK. Inflammatory bowel disease associated knowledge in South Indian populations: rational Study. Afri Health Sci. 2023;23(2):442-50. https://dx.doi.org/10.4314/ahs.v23i2.51

Introduction

An Inflammatory Bowel Disease (IBD) is a chronic gastrointestinal disorder caused by the dysregulated immune response in the gut of the host intestinal microflora. IBD is comprised of idiopathic intestinal disease, characterized by its location with the involvement of disease in the bowel wall¹. Two types of IBD, ulcerative colitis (UC) and Crohn's disease (CD) are seen in which diffused inflam-

Corresponding author:

Sathyaprabha Gopalan, Department of Pharmacy, Annamalai University, Chidambaram, (Tamil Nadu) India. Tel no: +91-8144370038 Email: thivishaprabha@gmail.com mation of the colonic mucosa occurs in ulcerative colitis (UC)² whereas transmural ulceration on any portion of the gastrointestinal tract (GI) results in Crohn's disease (CD) ³. Crohn's disease can affect any region of the intestine in a discontinuous pattern involving the terminal ileum, cecum, perianal area, and colon. In contradiction, ulcerative colitis can affect part of the colon or the entire colon and the rectum in a continuous pattern⁴. A thick-ened submucosa, transmural inflammation, fissuring ulceration, and granulomas were exhibited histologically in Crohn's disease, whereas in ulcerative colitis the inflammation is limited to the mucosa, submucosa with cryptitis and crypt abscesses⁵.

The prevalence rate of IBD becomes rapid in developing countries with the changing view as the disease of the

African Health Sciences © 2023 Gopalan S et al. Licensee African Health Sciences. This is an Open Access article distributed under the terms of the Creative commons Attribution License (https://creativecommons.org/licenses/BY/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

western population in one-twenty million population. In India, the total case of IBD was the largest with a rate of 1.4 million population in 2010 next to the USA around 1.64 million cases⁶. Crohn's disease was more usual in South India than ulcerative colitis in North India. Population-based studies in India were very few, however, there is a greater number of IBD cases in younger patients with disease severity in their clinics and hospitals⁷. Epidemiological studies have been hindered by various factors like appropriate databases, registries, scarcity of healthcare and hospital-based population studies proposed the highest disease burden in Asian countries⁸.

Barriers in the management and IBD care of the patients have not been previously described by the pharmacist, however, there was no data on concerns with exposure and IBD knowledge9. Deficits in the identification of knowledge evaluation play a major role in the effect of disease management. Knowledge acquisition was an integral role in the diagnosis and treatment of self-management skills of the disease ¹⁰. Earlier studies by western countries explained the gaps in the level of knowledge specific to IBD complications and various treatment options. So routine assessment will be a requisite for chronic conditions of diseases like IBD¹¹. Educational resources and health care facilities for individual factors play a role in patient education and the interventional effect on patient outcomes. There were no parameters in the assessment of specific standards but intervention may substantially change the disease concern by providing structural information to the study population¹².

Aim

The purpose of the study was to evaluate the sociodemographic characteristics and the effectiveness of patient education in the pre-test and post-test of the prospective study design by measuring the level of knowledge in IBD patients. The hypothesis of the research would demonstrate that patient education may improve the knowledge scores in the post-test of the study.

Methods

Ethics Approval

The Institutional Human Ethics Committee (IHEC) approved for ethical clearance before the commencement of the study and the proposal number was EC/AP/591/10/2018. Participation of the patient in the study was enrolled after the informed written consent through the direct interview technique.

Study Design and Participants

A prospective interventional study was conducted at Kovai Medical Center and Hospital (KMCH) in the Department of Gastroenterology from November 2018 to July 2019 by a convenient sampling technique. A total of 40 patients were enrolled in the study based on their inclusion and exclusion criteria. Inclusion criteria were patients with a diagnosis of IBD, adult population above eighteen years, and patient attentiveness during the study phase. Patients with intermediate colitis, irritable bowel syndrome, diagnosis of colorectal cancer, and severe illness patients were excluded from the study.

Data Collection Tool

The performa was specially designed that comprised of the closed-ended questionnaire with sociodemographic characteristics such as age, gnder, marital status, area of residence, social behavior (alcohol & smoking), and family history.

A validated IBD-KNOW questionnaire was used after obtaining permission from the author to measure the knowledge scores of the participants (Hyuk Yoon et al 2017). The Cronbach-alpha value of IBD-KNOW questionnaire $\alpha = 0.952$. It is the first tool to be used in the South Indian population, as no previous studies were performed on disease-related knowledge.

By application of IBD-KNOW, predictive factors in disease related to knowledge levels can be evaluated. The questionnaire comprised of 24 item questions and scoring was calculated as one point for each correct answer (Yes =1 No=0 & Don't Know=0). The knowledge score was measured by a ratio as the correct answer rate for each question.

A patient information leaflet was developed logically and a readability assessment was done with the Flesch-Kincaid reading score used for the educational session of the patients during the visit. A pilot study was performed on a small population to examine the difficulty of respondents in interpreting the questionnaire.

Data Collection Procedure

The patients were enrolled by the convenient method of sampling (n=40) based on inclusion and exclusion criteria. In the baseline visit (V0), the patient's data was collected using a proforma and IBD-KNOW questionnaire. Patient educational resources were provided to the participants with standard care during first visit (V1). After

12 weeks, patients who attended the second visit (V2) for physician review were assessed for IBD-KNOW in the post-test. The data were analyzed by R program and interpreted accordingly.

Data analysis

Statistical analysis of the variables was conducted using the R program (Statistical tool for data analysis). The inter item correlation was calculated with the response rate of each question in both the pre-test and post-test using the Pearson correlation test. The chi-square test and independent student t-test were used for the estimation of study participants. The knowledge response rate was calculated as mean in percentage (%) in the study population and categorized as good for a maximum rate of above 70 %, average knowledge response of 35% to 70%, and a poor rate of knowledge response below 35%.

Results

Sociodemographic features in IBD patients

Among the 40 study population, the majority of patients were between 30 - 40 years 47.5%, with a female predominance of 62.5% than the male patients, marital status of a married person with 62.5%, Urban was greater than rural with 72.5%, Business patients was greater 27.5% with the disease, family history in 10% among the study population, among education status high school level with 47.5%, the social behavior of alcoholism in 15% and smoking habits with 17.5% as given in table 1.

Table1. Frequency distribution of Sociodemographic features

Characteristics	Frequency (n=40)	Percentage (%)	Chi Square test	*n value	
Age in Years	rrequency (n 10)		ein square test	p vulue	
20-30	7	17.5%			
30-40	19	47.5%		0.323	
40-50	12	30%	9.3		
50-60	1	2.5%			
Greater than 60	1	2.5%			
Gender				1	
Male	15	37.5%	10.40	0.007	
Female	25	62.5%	12.43		
Marital Status					
Married	25	62.5%			
Unmarried	11	27.5%	0.07	0.005	
Divorce	1	2.5%	0.86	0.995	
Widow	3	7.5%			
Area of Residen	ice			•	
Urban	29	72.5%	1.00	0.522	
Rural	11	27.5%	1.28	0.532	
Occupation	•	•		•	
Professional	7	17.5%			
Student	3	7.5%			
Home Maker	9	22.5%	22 77	0.001	
Business	11	27.5%	52.77		
Agriculture	4	10%			
Others	6	15%			
Educational Sta	itus			-	
Illiterate	4	10%			
Elementary	5	12.5%		0.013	
High School	19	47.5%			
Graduate	12	30%			
Family History	• •	•		-	
Yes	4	10%	5 20	0.076	
No	36	90%	5.58		
Alcoholism					
Yes	6	15%		0.254	
No	32	80%	5.38		
Past	2	5%			
Smoking					
Yes	7	17.5%		0.001	
No	27	67.5%	23.96		
Past	6	15%			

Note*: p< 0.05 significance p<0.00 strongly significance

Knowledge assessment in IBD patients

In the pre-test, the mean correct answer rate for 24 items in the question was 40.7%. The questions related to the treatment in the use of biological agents "Q17", usage of enema or suppository in UC "Q18", and in women-related questions "Q23" the rate of the correct answer was at least 12.5%. The highest rate of response was identified in "Q9" for the development of anemia after severe inflammation and in "Q14" the persistence of bowel inflammation even after treatment initiation was 72.5%. But the minimum response of < 35% existed in most of the questions related to anatomy 32.5%, function 27.5%, the occurrence of disease 30%, management 12.5%, long term effect and surgery 30%. (Table 2)

Knowledge	Pre-test (n=40)	Post-test (n=37)
Response Rate		
Maximum Rate	Q9 Risk factors Q14 Symptoms	Q2Anatomy O5 Diet
, , 0, 0	QTTSymptoms	Q8& Q10 Disease Occurrence
		Q9 Risk factors
		Q13& Q14 Symptoms
Average Rate	Q2 Anatomy	Q1 Anatomy
(35 %- 70%)	Q3 Function	Q3& 4 Function
	Q5 Diet	Q6 Smoking
	Q7 Risk factors	Q7 Risk factors
	Q8& 10 Disease occurrences	Q11& 12 Disease occurrences
	Q13 Symptoms	Q15&16 Management
	Q15&16 Management	Q19, 20 & 21 Long term
	Q21 Long term effects &	effects & surgery
	surgery	Q24 Vaccination
Minimum	Q1 Anatomy	Q17 & 18 Management
Rate < 35%	Q4 Function	Q22 & 23 Pregnancy
	Q6 Smoking	
	Q11& 12 Disease	
	occurrences	
	Q17&18 Management	
	Q19& 20 Long term effects	
	& surgery	
	Q22 &23 Pregnancy	
	Q24 Vaccination	

Table 2: Response rate in Knowledge score between Pre-test and Post-test

The patient education conducted through face-to-face interviews of enrolled patients was educated with a patient information leaflet for five minutes in the baseline study of visit 1 regarding the type of disease (occurrence, anatomy, function), risk factors, complication, social behavior, lifestyle modifications and management of the disease.

On the second visit (V2) after 12 weeks, the patient enrollment was biased from (n = 40) to (n = 37) in the post-test of the study. Bias may be due to irregularity in the patient review with the physician or lack of time due to their work. The mean rate of the correct answer in the post-test was 53.37%. The lowest answer rate was

in "Q23" women-related questions at as13.5% and the highest rate was in "Q9" for the development of anemia after severe inflammation at 89.2%. The maximum response was ascertained in "Q2" anatomy as 72.9%, "Q5" diet as 78.4%, "Q8" as 81.1% & "Q10" as 72.9% disease occurrence, "Q13" & "Q14" Symptoms 86.5% (Figure 1).

There exists a significant difference in response rate between the pre-test and post-test in the educational group of the patients by acceptance of an alternative hypothesis. The degree of correlation between the variables was within the limits of -0.1 to 0.1. (Table 3)



Fig 1: Distribution of response rate in domains of IBD knowledge questions

Table 3: Description of correct answer rate between pretest and post-test of	the study
--	-----------

Domains in IBD KNOW	Pre- test	Item Total	Post- test	Item Total
Questionnaire	n=40 (%)	Correlation	n=37 (%)	Correlation
Q1.The terminal ileum is the last part of the small bowel located in right lower abdomen.	13(32.5%)	0.831	19(51.4%)	0.805
Q2. The rectum is part of the colon starts approximately 15cm from the anus and finishes at the anus	20 (50%)	0.818	27(72.9%)	0.724
Q3 .The function of the colon is to absorb nutrients	15 (37.5%)	0.801	20(54.1%)	0.734
Q4. People can survive without the colon, but not without the small bowel	11 (27.5%)	0.803	14(37.8%)	0.828
Q5. Specific foods to be avoided in IBD are well known	22 (55%)	0.333	29(78.4%)	0.671
Q6. Smoking cessation is important to prevent worsening of Crohns disease	14 (35%)	0.729	19(51.3%)	0.892
Q7. Risk of IBD increases with family history of the condition	18 (45%)	-0.187	21(56.8%)	0.87
Q8. IBD can develop in all age groups, but is more frequent at younger ages	25 (62.5%)	0.325	30(81.1%)	0.589
Q9. Anemia may develop if severe inflammation persists	29 (72.5%)	0.571	33(89.2%)	0.766
Q10. Crohns disease can occur anywhere in the digestive tract, from the mouth to the anus	24 (60%)	0.256	27(72.9%)	0.681
Q11. Ulcerative colitis rarely involves the rectum	12 (30%)	-0.166	16(43.2%)	0.809
Q12. IBD can involve organs other than the bowels.	14 (35%)	0.823	16(43.2%)	0.879
Q13.IBD is considered cure if symptoms do not recur after a few years.	22 (55%)	0.833	26(70.3%)	0.972
Q14.Inflammation in the bowels may persist even if the symptoms improve after treatment initiation.	29 (72.5%)	0.696	32(86.5%)	0.766
Q15.Long term steroid administration is advised to reduce inflammation recurrence.	22 (55%)	0.833	24(64.9%)	0.839

Q16. Constant blood monitoring is				
indicated for patients who are				
on immunocompromised agents such	15 (37.5%)	0.801	20(54.1%)	0.934
as Azathioprine, because their WBC				
may decrease.				
Q17.Biological agents are mainly used	5 (12 50/)	0.51(12(22,40/)	0.7(0
in patients with mild symptoms.	5 (12.5%)	0.516	12(32.4%)	0.769
Q18. Suppository or enema is used to				
treat cecal inflammation in patients	5 (12.5%)	0.308	8(21.6%)	0.557
with Ulcerative Colitis.	· · ·			
Q19. Patients with IBD for 8-				
10 yrs should have colorectal	13 (32.5%)	0.478	18(48.6%)	0.848
screening.			``	
Q20. Permanent colostomy is				
performed if surgery is indicated for	12 (30%)	0.491	21(56.8%)	0.649
patients with Ulcerative colitis.				
Q21. Patients with Crohns disease of				
the small bowel may be cured after	18 (45%)	0.51	23(62.2%)	0.835
surgery.	``´´		``	
Q22. Patients with IBD should stop all				
the medications when considering	10 (25%)	0.756	12(32.4%)	0.737
pregnancy.				
Q23. Most patients with IBD are	C (10 CO()	0.411	5(12,50/)	0.470
advised cesarean section delivery.	5 (12.5%)	0.411	5(13.5%)	0.4/9
Q24. Immunocompromised patients				
with IBD should avoid any kind of	14 (35%)	0.686	18(48.6%)	0.707
vaccination	<u>``´</u>		, , ,	

Discussion

This was the first study in south India on health-related knowledge determination which forms the base for the educational program and further follow-up in IBD patients. The age factor was reliable to the study that disease was more prevalent in the mean age of 33.5 ± 13.1 years with the greater years of age between 30 to 40 years¹³. The predominance of females over males was similar to the earlier studies ¹⁴. Family history showed similarities to north India than the developed countries the prevalence among the first relative was greater in siblings than the parents with a higher probability ¹⁵. The results of various studies described the relation between IBD and alcoholic habits as they do not know the frequency and quantity of alcohol intake by IBD patients and resembled the present study ¹⁶. The area of the residence (urban and

rural) as there was a positive association of IBD in urban people due to lifestyle which may exacerbate or induce the IBD condition¹⁷.

The present study on knowledge assessment was based on IBD -KNOW questionnaire, which was exempted from other studies related to CCKNOW (Crohn's Colitis Knowledge questionnaire) which had few problems in the clinical evaluation of IBD knowledge. However, the usage of biologicals in IBD treatment was the updated item in the IBD KNOW questionnaire but the question " Q17 " about biologicals in the management of mild symptoms was less in the pre-test compared to the post-test¹⁸. The quality of care by avoiding vaccination in immunocompromised patients " Q24 " was relatively effective in the management of IBD ¹⁹. Similarly, the present study explored a few variations than the pretest of 35% with a low response rate. In IBD women patient's knowledge regarding the plan for pregnancy to stop the medication in " Q22 " was the lowest in both pre-test and post-test similar to the study stating that females were less than male patients as they may face problems during pregnancy 20. The questions related to the complication were greater in IBD patients and this was reliable to the previous study²¹. The correct answer rate in the drug management was lesser than 50% both in pre-test as well as post-test mentions for reliability in older studies²². The improvement in knowledge score in the post-test was reliable to the study stating that formal education supports the IBD population like other chronic diseases and higher knowledge levels had the least worries and concerns about the disease. The present study was not consistent with the past study with reduced health care on long-term educational benefits²³. The outcome will be more effective when education on the management with drugs were provided by proper training in the IBD patients was similar to the present study²⁴. The appropriate review, consistent follow-up, and drug compliance were the significant features in the management of IBD for lowered relapse in the frequency of disease²⁵.

Conclusion

The study revealed the effectiveness of education in posttest by greater than 50% in disease associate knowledge. The humanistic approach by pharmacists aids the patients to motivate and support in reducing the disease severity. The present study recommends affording suitable education to improve knowledge levels that help to manage the disease and improves the coping strategy. Recently there was a swift in IBD incidence, but the progress of effective educational programs on management for IBD was still scarce in India. Effective educational modalities for disease-related knowledge can be provided by telemonitoring, web-based teaching, and tele-education. Also training the health care professionals may lessen the disease burden in IBD patients. As a consequence, of the study, there is a need for the development of innovative educational methods to enable continuing education for chronic disease which can be easily accessible and reliable for IBD patients.

Acknowledgments

Authors wish to thank KMCRET for performing research work.

Authors Contribution

Conceptualization and methodology- Dr. S. Aravindh. Data collection, Data analysis and interpretation- Mrs. G. Sathyaprabha.

Drafting the article- DR.K.T.Manisenthilkumar. Revising -DR. N. Srinivasan.

Conflict of Interest

Authors declare there is no conflict of interest.

Funding/ Support

Nil.

Ethical Consideration

Proposal number of the study was EC/AP/591/10/2018.

References

1. Colombel JF, Shin A, Gibson PR. AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients with Inflammatory Bowel Disease: Expert Review. *Clin Gastroenterol Hepatol.* 2019 Feb; 17(3):380-390.e1 Available from DOI: 10.1016/j.cgh.2018.08.001.

2. Magro F, Langner C, Driessen A et al. European Society of Pathology (ESP) and the European Crohn's and Colitis Organisation (ECCO), European consensus on the histopathology of inflammatory bowel disease. *J Crohns Colitis.* 2013 Nov10; 7(10), 827–851. Available from DOI:10.1016/j.crohns.2013.06.001

3. Dmochowska N, Wardill HR, Hughes PA. Advances in Imaging Specific Mediators of Inflammatory Bowel Disease. *Int J Mol Sci.* 2018 Aug 21;19(9):2471. Available from DOI: 10.3390/ijms19092471.

4. Jung SA. Differential diagnosis of inflammatory bowel disease: what is the role of colonoscopy? *Clin Endosc.* 2012 Sep 9;45(3):254-62. DOI: 10.5946/ce.2012.45.3.254. PM-CID: PMC3429747

5. Guan Q. A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. *J Immunol Res.* 2019 Dec 1:7247238. Available from DOI:10.1155/2019/7247238.

6. Sood A, Midha V, Sood N, Bhatia AS, Avasthi G. Incidence and prevalence of ulcerative colitis in Punjab, North India. *Gut.* 2003 Nov 16;52(11):1587-90. Available from DOI: 10.1136/gut.52.11.1587. PMID: 14570727

7. Ray G. Inflammatory bowel disease in India - Past, present and future. *World J Gastroenterol.* 2016 Sep 28;22(36):8123-36. Available from DOI: 10.3748/wjg. v22.i36.8123. PMID: 27688654

8. Kedia S, Ahuja V. Epidemiology of Inflammatory Bowel Disease in India: The Great Shift East. *Inflamm Intest Dis.* 2017 Nov 8;2(2):102-115 Available from DOI: 10.1159/000465522.

9. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut.* 2019;68(3): s1-s106.Available from doi:10.1136/gutjnl-2019-318484

10. Park KT et al. The Cost of Inflammatory Bowel Disease: An Initiative from the Crohn's & Colitis Foundation. *Inflamm Bowel Dis.* 2020 Jun 18 ;26(1):1-10. Available from DOI:10.1093/ibd/izz104.

11. Hou JK et al. Assessment of Gaps in Care and the Development of a Care Pathway for Anemia in Patients with Inflammatory Bowel Diseases. *Inflamm Bowel Dis.* 2017 Jan 9 ;23(1):35-43. Available from DOI: 10.1097/MIB.000000000000953.

12. Nakase, H., Uchino, M., Shinzaki, S. et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. *J Gastroenterol.* 2021 Jun; 56: 489–526. Available from https://doi.org/10.1007/s00535-021-01784-1.

13. Gonçalves TC, Dias de Castro F, Machado JF, Moreira MJ, Rosa B, Cotter J. Impact of the age of diagnosis on the natural history of ulcerative colitis. *Rev Esp Enferm Dig.* 2015 Oct;107(10):614-21. Available from DOI: 10.17235/reed.2015.3736/2015.

14. Yazdanbod A et al. Epidemiologic profile and clinical characteristics of ulcerative colitis in northwest of Iran: a 10-year review. *Trop Gastroenterol.* 2010; 31(4):308-11.

15. Gupta A et al . Familial aggregation of inflammatory bowel disease in patients with ulcerative colitis. *Intest Res.* 2017 July; 15(3):388-394. Available from https://doi. org/10.5217/ir.2017.15.3.388

16. Hsu T-Y et al. Effect of Alcoholic Intoxication on the Risk of Inflammatory Bowel Disease: A Nationwide Retrospective Cohort Study. *Plos One*. 2016 Nov 1; 11(11):

e0165411. Available from https://doi.org/10.1371/ journal

17. Mahmud N, Weir DG. The urban diet and Crohn's disease: is there a relationship? *EurJ Gastroenterol Hepatol* 2001 Feb; 13:93-5. Available from DOI: 10.1097/00042737-200102000-00001.

18. Park SC, Jeen YT. Current and emerging biologics for ulcerative colitis. *Gut Liver*. 2015 Jan; 9:18–27. Available from DOI: 10.5009/gnl14226

19. Shah R, Hou JK. Approaches to improve quality of care in inflammatory bowel diseases. *World J Gastro-enterol.* 2014 July 28;20:9281–9285. Available from DOI: 10.3748/wjg. v20.i28.9281

20. Makharia GK. Quality of care in Crohn's disease. *World J Gastrointest Pathophysiol.* 2014 Nov 15 ;5(4):462-6. Available from DOI:10.4291/wjgp. v5.i4.462

21. Subasinghe D, Wijekoon NS, Nawarathne NM, Samarasekera DN. Disease-related knowledge in inflammatory bowel disease: experience of a tertiary care centre in a developing country in South Asia. *Singapore Med J.* 2010 ;51(6):484-9.

22. Vernon-Roberts A, Gearry RB, Day AS. The Level of Public Knowledge about Inflammatory Bowel Disease in Christchurch, New Zealand. *Inflamm Intest Dis.* 2020;5(4):205-211.Available from DOI: 10.1159/000510071

23. BM Waters, L Jensen, RN Fedorak. Effects of formal education for patients with inflammatory bowel disease: A randomized controlled trial. *Can J Gastroenterol* 2005;19(4):235-244.

24. Yoo YS, Cho OH, Cha KS. Disease-Related Knowledge and Information Needs Among Inflammatory Bowel Disease Patients in Korea. *Gastroenterol Nurs.* 2015 Nov- Dec; 38(6):455-63. Available from https://doi. org/10.1097/SGA.

25. Sathyaprabha, G, Srinivasan N, Aravindh S, Manisenthil Kumar KT. Evaluation of clinical characteristics and knowledge in inflammatory bowel disease patients. *J. Evol. Med. Dent. Sci* 2021; 10(29):2202-2207.